Ultragenyx Receives a Buy from J.P. Morgan

By Jason Carr

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Ultragenyx (NASDAQ: RARE) on November 7 and set a price target of $106. The company’s shares closed yesterday at $61.17.

According to TipRanks.com, Kasimov is ranked 0 out of 5 stars with an average return of -13.9% and a 27.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Karyopharm Therapeutics, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Ultragenyx is Strong Buy and the average price target is $96.25, representing a 57.3% upside.

In a report issued on November 1, Piper Jaffray also reiterated a Buy rating on the stock with a $82 price target.

The company has a one year high of $117.12 and a one year low of $46.52. Currently, Ultragenyx has an average volume of 581.2K.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is neutral on the stock. Most recently, in February 2016, Theodore Alan Huizenga, the Controller and PAO of RARE bought 1,000 shares for a total of $21,000.

Ultragenyx Pharmaceutical, Inc. is a clinical-stage biotechnology company that is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. It intends to build therapies to address these clinically underserved diseases. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.